Form 4: Dyne Therapeutics Director Granted 35,000 Stock Options at $11.96 Exercise Price

Dyne Therapeutics, Inc. Director David Charles Lubner was granted 35,000 stock options with an exercise price of $11.96, vesting fully by May 2026.

Summary

• David Charles Lubner, a Director of Dyne Therapeutics, Inc. (DYN), was granted 35,000 stock options on May 30, 2025.
• Each option has an exercise price of $11.96.
• The options are for the purchase of 35,000 shares of Dyne Therapeutics Common Stock.
• The options are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service.
• The options have an expiration date of May 29, 2035.
• The reporting person's beneficial ownership of derivative securities following this transaction is 35,000 options.
• A Limited Power of Attorney was executed on June 3, 2025, by David Lubner, appointing John Cox, Erick Lucera, Dan Wilson, and Ron Caponigro as attorneys-in-fact for Section 16 reporting obligations.

Sentiment

Score: 6

Explanation: The document reports a standard equity compensation grant to a director, which is a neutral to slightly positive event as it aligns director incentives with shareholder value. There are no negative financial or operational disclosures.

Positives

• The grant of 35,000 stock options to Director David Charles Lubner aligns his interests with long-term shareholder value, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule, tied to continued service, incentivizes the director's ongoing commitment to the company.

Negatives

• The exercise price of $11.96 means the options only have intrinsic value if the stock price rises above this level, representing a potential future dilution if exercised.

Risks

• The value of the granted stock options is subject to market fluctuations and the future performance of Dyne Therapeutics' stock price. If the stock price does not exceed the exercise price of $11.96, the options may expire worthless.
• The vesting of options is subject to continued service, meaning the director would forfeit unvested options if service ceases before the vesting date.

Future Outlook

The document primarily details a past transaction (option grant) and its future vesting schedule. It does not provide broader forward-looking statements or guidance on company performance or strategy.

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director, common practice in the biotechnology and pharmaceutical industries to align management and director incentives with shareholder interests. Such grants are a standard component of executive and director compensation packages in growth-oriented sectors like biotech, where long-term value creation is paramount.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation practice across the biotechnology and pharmaceutical industries, similar to companies like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), which frequently use equity-based incentives to attract and retain talent.
• The vesting schedule, typically over one year or tied to annual meetings, is standard for director grants, ensuring continued engagement.
• The exercise price being set at the market price on the grant date is also a standard practice for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to David Charles Lubner, a Director of Dyne Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive alignment of director incentives with shareholder interests, as the options gain value only if the stock price increases. However, future exercise of these options could lead to minor dilution.
• Employees: No direct impact on employees is mentioned, but such grants are part of a broader compensation philosophy that may influence employee equity programs.

Next Steps

• The granted stock options are scheduled to vest in full on the earlier of May 30, 2026, or the date of Dyne Therapeutics' 2026 Annual Meeting of Stockholders, subject to David Charles Lubner's continued service.

Key Dates

Recommendation

Keywords

Dyne Therapeutics, DYN, Stock Options, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Biotechnology, Pharmaceuticals